PSP-001 is under clinical development by Prosit Sole Biotechnology (Beijing) and currently in Phase I for Norovirus Infections. According to GlobalData, Phase I drugs for Norovirus Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the PSP-001 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PSP-001 overview
PSP-001 is under development for treatment of chronic norovirus enteritis, coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The drug candidate is a pegylated human interferon lambda 1- lambda 3 chimeric protein, that acts by targeting interferon lambda receptor 1 (IL28RA or IFNLR1). It is developed based on Prositsole Protein Optimize Platform (P-POP). It was under development for the treatment of chronic hepatitis B, viral wheezing, cytomegalovirus infection.
Prosit Sole Biotechnology (Beijing) overview
Prosit Sole Biotechnology (Beijing) is developing innovative protein therapeutics that address the unmet medical needs for life-threatening rare diseases. It is headquartered in Beijing, China.
For a complete picture of PSP-001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
